Spelling suggestions: "subject:"interleukine "" "subject:"interleukines ""
21 |
Cathosis: Cathepsins in Particle-induced Inflammatory Cell Death: A DissertationOrlowski, Gregory M. 01 May 2015 (has links)
Sterile particles underlie the pathogenesis of numerous inflammatory diseases. These diseases can often become chronic and debilitating. Moreover, they are common, and include silicosis (silica), asbestosis (asbestos), gout (monosodium urate), atherosclerosis (cholesterol crystals), and Alzeihmer’s disease (amyloid Aβ). Central to the pathology of these diseases is a repeating cycle of particle-induced cell death and inflammation. Macrophages are the key cellular mediators thought to drive this process, as they are especially sensitive to particle-induced cell death and they are also the dominant producers of the cytokine responsible for much of this inflammation, IL-1β. In response to cytokines or microbial cues, IL-1β is synthesized in an inactive form (pro-IL-1β) and requires an additional signal to be secreted as an active cytokine. Although a multimolecular complex, called the NLRP3 inflammasome, controls the activation/secretion of IL-1β (and has been thought to also control cell death) in response to particles in vitro, the in vivo inflammatory response to particles occurs independently of inflammasomes. Therefore, I sought to better understand the mechanisms governing IL-1β production and cell death in response to particles, focusing specifically on the role of lysosomal cathepsin proteases. Inhibitor studies have suggested that one of these proteases, cathepsin B, plays a role in promoting inflammasome activation subsequent to particle-induced lysosomal damage, however genetic models of cathepsin B deficiency have argued otherwise. Through the use of inhibitors, state-of-the-art biochemical tools, and multi-cathepsin-deficient genetic models, I found that multiple redundant cathepsins promote pro-IL-1β synthesis as well as particle-induced NLRP3 activation and cell death. Importantly, I also found that particle-induced cell death does not depend on inflammasomes, suggesting that this may be why inflammasomes do not contribute to particle-induced inflammation in vivo. Therefore, my observations suggest that cathepsins may be multifaceted therapeutic targets involved in the two key pathological aspects of particle-induced inflammatory disease, IL-1β production and cell death.
|
22 |
Einfluß des Cyclooxygenase-2-Inhibitors NS-398 auf Proliferation und Apoptose von OvarialkarzinomzellinienFürstenberg, Antje 06 January 2005 (has links)
Mehrere Studien haben gezeigt, daß die Cyclooxygenase-2 (COX-2) eine bedeutende Rolle sowohl bei Entstehung als auch Progression maligner Tumoren spielt. COX-2-Inhibitoren werden bereits in klinischen Studien zur Krebstherapie getestet. COX-2 ist die induzierbare Isoform der Cyclooxygenase - dem Schlüsselenzym der Synthese von Prostaglandinen und anderen Eicosanoiden. Im Tier- und Zellkulturmodell konnten COX-Hemmer anti-Tumor-Effekte hervorrufen. Es ist jedoch unklar, ob diese Effekte durch Hemmung des COX-Enzyms oder durch COX-unabhängige Mechanismen vermittelt werden. Wir untersuchten daher die Auswirkung der COX-Inhibition zum einen durch den selektiven COX-2-Hemmer NS-398 sowie zum anderen durch COX-Isoform-spezifische RNA-Interferenz (RNAi) in zwei humanen Ovarialkarzinomzellinien (OVCAR-3 und SKOV-3). OVCAR-3 zeigte eine konstitutive COX-1-Expression und eine durch IL-1beta induzierbare COX-2-Expression. SKOV-3 war COX-1- und COX-2-negativ. IL-1beta führte bei OVCAR-3 zu einer vermehrten Produktion von Prostaglandin E2 (PGE2), die durch eine gegen die COX-2 gerichtete siRNA gehemmt werden konnte, wohingegen COX-1-siRNA keinen Effekt hatte. Das deutet darauf hin, daß die COX-2 die Hauptquelle von PGE2 in OVCAR-3 ist. 1mikroM NS-398 waren ausreichend, um die PGE2-Produktion und somit auch die COX-2 in OVCAR-3 zu inhibieren. Höhere Konzentrationen NS-398 (>10mikroM) hatten einen antiproliferativen Effekt. Auch in der COX-2-negativen Zellinie SKOV-3 trat diese Wachstumshemmung auf; sie war nicht durch exogene Zufuhr von PGE2 (10mikroM) reversibel. Durchflußzytometrische Zellzyklusanalyse ergab, daß der Wachstumshemmung in beiden Zellinien ein G0/G1-Zellzyklusarrest zugrunde liegt. Dagegen führten weder COX-1- noch COX-2-Ausschaltung durch RNAi zu ähnlichen Auswirkungen auf Proliferation bzw. Zellzyklus. Diese Ergebnisse zeigen, dass ein COX-2-unabhängiger Mechanismus für den durch NS-398 induzierten G0/G1-Arrest verantwortlich ist. / Several studies have provided evidence that the enzyme Cyclooxygenase-2 (COX-2) plays an important role in tumor development and progression. COX-2-inhibitors are already evaluated in clinical trials as cancer therapeutics. COX-2 is the inducible isoform of cyclooxygenase - the rate-limiting enzyme in the synthesis of prostaglandins and other eicosanoids. COX-inhibitors cause antitumor effects in animal models and in cell culture experiments. However, it is not clear, whether these effects are due to inhibition of the COX-enzyme or mediated via a COX-independent mechanism. We therefore investigated the effects of COX inhibition by the selective COX-2-inhibitor NS-398, as well as by COX-isoform specific RNA interference (RNAi) in the human ovarian carcinoma cell lines OVCAR-3 and SKOV-3. OVCAR-3 cells showed a constitutive expression of COX-1, and an inducible COX-2 expression. COX-2 was induced through stimulation with Interleukin-1beta, leading to production of high levels of Prostaglandin E2 (PGE2). SKOV-3 cells were negative for both COX isoforms. Selective COX-2-suppression by RNAi reduced PGE2 production in OVCAR-3, whereas COX-1-siRNA had no effect on PGE2 synthesis. Thus, COX-2 is the main source of PGE2 in OVCAR-3 cells. In these cells, 1microM NS-398 was sufficient to completely inhibit PGE2-synthesis - and thus the activity of the COX-2 enzyme. Increasing amounts of NS-398 (>10microM) had an antiproliferative effect. This growth inhibition was also observed in the COX-negative cell line SKOV-3, it could not be reverted by exogenous addition of PGE2 (10microM). Flowcytometric analysis of the cell cycle revealed that this growth inhibition was based on a G0/G1-cell-cycle-arrest. In contrast, suppression of COX-1 or COX-2 by RNAi had no effect on proliferation or cell cycle progression. These results suggest that a COX-independent mechanism is responsible for the G0/G1-arrest induced by NS-398.
|
23 |
Makropinozytose und Interleukin-1β-Sekretion nach Kalziumstimulation von Monozyten und Makrophagen von Patienten mit rheumatoider Arthritis und KontrollprobandenHahn, Magdalena 04 February 2020 (has links)
Monocytes and macrophages are mediator cells of cartilage and bone erosion in the synovia of rheumatoid arthritis (RA) patients due to secretion of the inflammatory cytokine Interleukin-1β (IL-1β). Calcium, phosphate and fetuin are liberated from the affected bone matrix, and the formation of calciproteinparticles (CPPs) is likely. IL-1β production in monocytes in vitro is stimulated by high concentrations of extracellular calcium. Additionally, the rise of extracellular calcium concentrations leads to increased macropinocytosis in mononuclear phagocytes. Flow cytometry analyses in this study show that peripheral blood monocytes from patients with RA perform more calcium stimulated macropinocytosis of the fluorescent dye calcein than monocytes from healthy donors. Stimulation of monocytes with calcium and preformed CPPs leads to more IL-1β production, quantified using ELISA, by monocytes from RA patients. Experiments with macrophages show similar results. Furthermore calcium-stimulated macropinocytosis and IL-1β secretion are significantly positively correlated. However, there was no connection of in vitro findings and the severity of RA in patients.:Abbildungsverzeichnis IV
Tabellenverzeichnis VI
Abkürzungsverzeichnis VII
1 Einleitung 1
1.1 Rheumatoide Arthritis 1
1.1.1 Epidemiologie und Klinik der rheumatoiden Arthritis 1
1.1.2 Ätiopathogenese der rheumatoiden Arthritis 1
1.2 Monozyten und Makrophagen 3
1.2.1 Inflammasomaktivierung und Interleukin-1β-Sekretion in Monozyten und Makrophagen 4
1.2.2 Makropinozytose in Monozyten und Makrophagen 6
1.2.3 Beitrag der Monozyten und Makrophagen zur rheumatoiden Arthritis 7
1.3 Kalzium – lokale Dysregulation trotz systemischer Regulation 9
1.3.1 Entstehung von Kalziumproteinpartikeln 10
1.3.2 Kurzportrait des G-Protein-gekoppelten Kalziumrezeptors CaSR 11
2 Fragestellungen 13
3 Forschungsdesign, Material und Methoden 15
3.1 Forschungsdesign 15
3.2 Materialien 15
3.2.1 Laborgeräte 16
3.2.2 Verbrauchsmaterialien 17
3.2.3 Materialien und Chemikalien 17
3.2.4 Medien, Lösungen und Puffer 19
3.2.5 Stimulanzien und Inhibitoren 20
3.2.6 Fluoreszenzfarbstoffe 20
3.2.7 Software 20
3.3 Methoden 21
3.3.1 Separation von PBMCs mittels Ficolldichtegradientenzentrifugation 21
3.3.2 Separation von Monozyten mittels negativer Magnetseparation 22
3.3.3 Differenzierung von Monozyten zu Makrophagen in Zellkulturbeuteln 23
3.3.4 Makropinozytose von Monozyten und Makrophagen in der Durchflusszytometrie 23
3.3.4.1 Makropinozytose von Calcein in Monozyten 24
3.3.4.2 Makropinozytose fluoreszenzgefärbter Kalziumproteinpartikel in Monozyten und Makrophagen 25
3.3.4.3 Inhibition der Makropinozytose in Monozyten 26
3.3.4.4 Auswertung der am Durchflusszytometer generierten Rohdaten mit FlowJo 26
3.3.5 Makropinozytose von Monozyten in der Fluoreszenzmikroskopie 28
3.3.6 Bestimmung der Interleukin-1β-Produktion von Monozyten und Makrophagen mittels ELISA 29
3.3.7 Erhebung des DAS28 33
3.3.8 Bestimmung von Laborparametern 33
3.4 Statistische Auswertung 33
4 Ergebnisse 35
4.1 Charakterisierung der Kohorten 35
4.2 Vorversuche zur Auswahl eines geeigneten Fluoreszenzfarbstoffes für die Detektion der Makropinozytose 37
4.3 Stimulation von Monozyten mit Kalzium zur Makropinozytose und Interleukin-1β-Produktion 39
4.3.1 Kalziumstimulierte Calceinaufnahme von Monozyten 39
4.3.2 Kalziumstimulierte Interleukin-1β-Produktion von Monozyten 44
4.4 Stimulation von Monozyten mit Kalzium zur Makropinozytose und Interleukin-1β-Produktion unter Zugabe von Kalziumproteinpartikeln 47
4.4.1 Kalziumstimulierte Aufnahme fluoreszierender Kalziumproteinpartikel 47
4.4.2 Kalziumstimulierte Interleukin-1β-Produktion in Monozyten unter Zugabe von Kalziumproteinpartikeln 51
4.5 Stimulation von Makrophagen mit Kalzium zur Makropinozytose und Interleukin-1β-Produktion 53
4.5.1 Kalziumstimulierte Makropinozytose von fluoreszierenden Kalziumproteinpartikeln in Makrophagen 53
4.5.2 Kalziumstimulierte Interleukin-1β-Produktion mit und ohne Zugabe von Kalziumproteinpartikeln in Makrophagen 54
4.5.3. Visualisierung von Monozyten und Makrophagen nach 16 Stunden Inkubation 57
4.6 Korrelation zwischen kalziumstimulierter Makropinozytose und Interleukin-1β-Sekretion 59
5 Diskussion 61
5.1 Kalziumstimulierte Makropinozytoseaktivität von Monozyten und Makrophagen 61
5.2 Kalziumstimulierte Interleukin-1β-Sekretion von Monozyten und Makrophagen 64
5.2.1 Auswirkung der Phosphatkonzentration im Zellkulturmedium auf die kalziumstimulierte Interleukin-1β-Sekretion von Monozyten und Makrophagen 65
5.2.2 Kalziumstimulierte Interleukin-1β-Sekretion von Monozyten und Makrophagen von RA-Patienten und Kontrollprobanden 66
5.3 Zusammenhang von kalziumstimulierter Makropinozytose und Interleukin-1β-Sekretion in Monozyten und Makrophagen von RA-Patienten und Kontrollprobanden 70
5.4 Ausblick und offene Fragen 71
6 Zusammenfassung der Arbeit 73
8 Erklärung über die eigenständige Abfassung der Arbeit 88
9 Danksagung 89
|
24 |
Klonierung und Charakterisierung des Interleukin-1beta-Systems im Gehirn von Callithrix jacchus / Cloning and characterization of the interleukin-1beta-system in the brain of Callithrix jacchusKöster-Patzlaff, Christiane 03 July 2003 (has links)
No description available.
|
25 |
Les apoB-lipoprotéines en tant que modulateurs de la fonction du tissu adipeux et des facteurs de risque du diabète de type 2 chez l'humainBissonnette, Simon 12 1900 (has links)
Le diabète de type 2 (DT2) est une maladie chronique affectant 3 millions de canadiens. Une augmentation progressive de la résistance à l'insuline (RI) et de la sécrétion d'insuline est observée chez des sujets normoglycémiques bien avant la survenue du DT2. La moindre fonction du tissu adipeux blanc (TAB) est centrale dans le développement du DT2 car elle accroît le flux d'acides gras vers les tissus périphériques, y induisant la RI, l'hyperinsulinémie et l’inflammation chronique.
Durant ma maîtrise, nous avions démontré que les lipoprotéines de basses densité (LDL) natifs réduisent la différentiation et la fonction des adipocytes et induisent la dysfonction du TAB humain. De plus, nous avions montré qu'un taux plasmatique élevé d'apolipoprotéine B (apoB), indiquant un nombre élevé d'apoB-lipoprotéines dont principalement les LDL, est associé à la RI, la sécrétion d'insuline gluco-stimulée (SIGS) élevée, la clairance plasmatique retardée des gras alimentaires et la moindre fonction du TAB chez 81 sujets obèses non diabétiques. Afin de déterminer si l'apoB plasmatique permet aussi d'identifier les sujets obèses répondant le mieux à une diète hypocalorique en termes de réduction des facteurs de risque du DT2, nous avons testé l'effet d'une intervention hypocalorique de six mois. Parmis 59 sujets qui ont terminés l’intervention, nous avons mesuré une diminution de la SIGS et une amélioration de la fonction du TAB seulement chez les sujets avec apoB plasmatique élevée. Toutefois, les mécanismes de ces effets délétères possibles des apoB-lipoprotéines n'avaient pas été explorés.
Des évidences suggèrent que l'activation chronique de l'inflammasome Nucleotide- binding domain and Leucine-rich repeat Receptor containing a Pyrin domain 3 (NLRP3) et la sécrétion d'interleukine-1b (IL-1b) promeuvent la dysfonction du TAB et la RI systémique.
Cependant, les signaux métaboliques induisant l'inflammasome NLRP3 dans le TAB humain sont inconnus. Afin de tester si l'activation de l'inflammasome NLRP3/système IL-1b participe au mécanisme précédemment identifié liant les apoB-lipoprotéines et les facteurs de risque du DT2, nous avons investigué l'association et l'effet direct des apoB-lipoprotéines sur le système IL-1b. Nous avons démontré chez 81 sujets obèses non-diabétiques que les individus avec apoB plasmatique élevée montrent un taux élevé d'antagoniste du récepteur à l'IL-1 (IL-1Ra) plasmatique, un marqueur de l'activation systémique de la voie IL-1b. Aussi, les associations entre l'apoB plasmatique élevée et la RI et SIGS étaient statistiquement dépendantes des niveaux d'IL-1Ra plasmatique. Dans une autre population de 32 sujets, nous avons démontrés que ceux avec apoB plasmatique élevée ont une sécrétion augmentée d'IL-1b par le TAB ex vivo. Les relations entre l'apoB plasmatique, la clairance plasmatique retardée des gras alimentaires et la sécrétion de C-peptide glucostimulée étaient statistiquement dépendantes de la sécrétion d'IL- 1b du TAB. Puis, les LDL natifs ajoutés au TAB ex vivo induisaient la sécrétion d'IL-1b, y agissant en tant que signaux d'amorçage (1er signal de l'inflammasome NLRP3/système IL-1b).
En conclusion, ces résultats suggèrent que les LDL natifs, forme principale d'apoB- lipoprotéines, régulent positivement l'inflammasome NLRP3 du TAB humain. Ceci pourrait expliquer la dysfonction du TAB, l'hyperinsulinémie et l'incidence élevée du DT2 présents chez les sujets avec apoB plasmatique élevée. En outre, ils suggèrent que l'apoB plasmatique élevée pourrait être un biomarqueur permettant d'identifier les sujets obèses qui répondraient le mieux à la diète hypocalorique afin de réduire le risque de DT2. / Type 2 diabetes (T2D) is chronic disease affecting 3 million Canadians and a new case is diagnosed every 3 minutes in Canada. Long before the onset of T2D, a progressive increase in insulin resistance (IR) and insulin secretion is observed in normoglycemic subjects. A decreased white adipose tissue (WAT) function is central to the development of T2D as it promotes an increased fatty acid flux to peripheral tissues, inducing IR, hyperinsulinemia and chronic inflammation.
During my MSc, we reported that low density lipoproteins (LDL) reduce the differentiation and function of adipocytes and induce the dysfunction of human WAT. Moreover, we showed that elevated plasma apolipoprotein B (apoB), indicating high numbers of circulating apoB-lipoproteins mainly in the form of LDL, is associated to IR, elevated glucose-induced insulin secretion (GIIS), delayed postprandial plasma clarance of fat and reduced WAT function in 81 non-diabetic obese subjects. To explore whether apoB also identifies obese subjects who best respond to weight loss to reduce risk factors for T2D, we tested the effect of a 6 months hypocaloric diet. We showed in the 59 completers of the hypocaloric intervention that the decrease in GIIS and increase in WAT function were significant in subjects with high plasma apoB but not in subjects with low plasma apoB. However, the mechanism underlying the negative effects apoB-lipoproteins was yet unexplored.
Chronic activation of the Nucleotide-binding domain and Leucine-rich repeat Receptor containing a Pyrin domain 3 (NLRP3) inflammasome and secretion of interleukin-1b (IL-1b) promote WAT dysfunction and systemic IR. However, endogenous metabolic signals that induce the activation of WAT NLRP3 inflammasome are unknown. To test if the activation of the NLRP3 inflammasome/ IL-1b system is an underlying mechanism linking apoB- lipoproteins to risk factors for T2D, we examined the association and direct effect of apoB- lipoproteins on the IL-1b system. We observed in our cohort of 81 non-diabetic obese subects that subjects with high plasma apoB have higher plasma IL-1 receptor antagonist (IL-1Ra), which is an marker of systemic activation of the Il-1b pathway. Furthermore, the associations between high plasma apoB and IR and GIIS were statistically dependent on plasma IL-1Ra. Additionnaly, in a separate population of 32 subjects, we demonstrated that subjects with high plasma apoB have higher ex vivo WAT IL-1b secretion. The relation between plasma apoB and delayed postprandial plasma fat clearance and elevated glucose-induced C-peptide secretion were statistically dependent on WAT IL-1b secretion. Finally, native LDLs directly induce IL- 1b secretion from ex vivo WAT, acting primarily as priming signals (i.e. the first signal leading to activation of the NLRP3 inflammasome/ IL-1b system).
In conclusion, the findings from this thesis suggest that native LDL, the main form of apoB-lipoproteins, upregulate human WAT NLRP3 inflammasome. This may explain WAT dysfunction, hyperinsulinemia and higher incidence of T2D in subjects with high plasma apoB. Moreover, they suggest that high apoB may serve as biomarker to identify obese subjects who best respond to a hypocaloric-intervention to reduce the risk of T2D.
|
26 |
Resveratrol modulates interleukin-1beta-induced phosphatidylinositol 3-kinase and nuclear factor kappaB signaling pathways in human tenocytesBusch, F., Mobasheri, A., Shayan, P., Lueders, C., Stahlmann, R., Shakibaei, M. January 2012 (has links)
No / Resveratrol, an activator of histone deacetylase Sirt-1, has been proposed to have beneficial health effects due to its antioxidant and anti-inflammatory properties. However, the mechanisms underlying the anti-inflammatory effects of resveratrol and the intracellular signaling pathways involved are poorly understood. An in vitro model of human tenocytes was used to examine the mechanism of resveratrol action on IL-1beta-mediated inflammatory signaling. Resveratrol suppressed IL-1beta-induced activation of NF-kappaB and PI3K in a dose- and time-dependent manner. Treatment with resveratrol enhanced the production of matrix components collagen types I and III, tenomodulin, and tenogenic transcription factor scleraxis, whereas it inhibited gene products involved in inflammation and apoptosis. IL-1beta-induced NF-kappaB and PI3K activation was inhibited by resveratrol or the inhibitors of PI3K (wortmannin), c-Src (PP1), and Akt (SH-5) through inhibition of IkappaB kinase, IkappaBalpha phosphorylation, and inhibition of nuclear translocation of NF-kappaB, suggesting that PI3K signaling pathway may be one of the signaling pathways inhibited by resveratrol to abrogate NF-kappaB activation. Inhibition of PI3K by wortmannin attenuated IL-1beta-induced Akt and p65 acetylation, suggesting that p65 is a downstream component of PI3K/Akt in these responses. The modulatory effects of resveratrol on IL-1beta-induced activation of NF-kappaB and PI3K were found to be mediated at least in part by the association between Sirt-1 and scleraxis and deacetylation of NF-kappaB and PI3K. Overall, these results demonstrate that activated Sirt-1 plays an essential role in the anti-inflammatory effects of resveratrol and this may be mediated at least in part through inhibition/deacetylation of PI3K and NF-kappaB.
|
27 |
Resveratrol suppresses interleukin-1beta-induced inflammatory signaling and apoptosis in human articular chondrocytes: potential for use as a novel nutraceutical for the treatment of osteoarthritisShakibaei, M., Csaki, C., Nebrich, S., Mobasheri, A. January 2008 (has links)
No / Osteoarthritis is an inflammatory disease of load-bearing synovial joints that is currently treated with drugs that exhibit numerous side effects and are only temporarily effective on pain, the main symptom of the disease. Consequently, there is an acute need for novel, safe and more effective chemotherapeutic agents for the treatment of osteoarthritis and related arthritic diseases. Resveratrol is a phytoalexin stilbene produced naturally by plants including red grapes, peanuts and various berries. Recent research in various cell models has demonstrated that resveratrol is safe and has potent anti-inflammatory properties. However, its potential for treating arthritic conditions has not been explored. In this study we provide experimental evidence that resveratrol inhibits the expression of VEGF, MMP-3, MMP-9 and COX-2 in human articular chondrocytes stimulated with the pro-inflammatory cytokine IL-1beta. Since these gene products are regulated by the transcription factor NF-kappaB, we investigated the effects of resveratrol on IL-1beta-induced NF-kappaB signaling pathway. Resveratrol, like N-Ac-Leu-Leu-norleucinal (ALLN) suppressed IL-1beta-induced proteasome function and the degradation of IkappaBalpha (an inhibitor of NF-kappaB) without affecting IkappaBalpha kinase activation, IkappaBalpha-phosphorylation or IkappaBalpha-ubiquitination which suppressed nuclear translocation of the p65 subunit of NF-kappaB and its phosphorylation. Furthermore, we observed that resveratrol as well as ALLN inhibited IL-1beta-induced apoptosis, caspase-3 activation and PARP cleavage in human articular chondrocytes. In summary, our results suggest that resveratrol suppresses apoptosis and inflammatory signaling through its actions on the NF-kappaB pathway in human chondrocytes. We propose that resveratrol should be explored further for the prophylactic treatment of osteoarthritis in humans and companion animals.
|
Page generated in 0.0405 seconds